Skip to main content
×
×
Home

Chemotherapy for Hodgkin's lymphoma in a patient receiving clozapine for treatment-resistant schizophrenia: use of the Mental Capacity Act 2005

  • Florence Elizabeth Chamberlain (a1), Nicholas Walsh (a2) and Jan Falkowski (a3)
Summary

Treatment resistance occurs in approximately 30% of individuals with schizophrenia and is commonly treated with clozapine. Nodular sclerosing Hodgkin's lymphoma is a subtype of Hodgkin's lymphoma predominantly affecting those under 50 years of age. In this case report, an individual with treatment-resistant schizophrenia developed nodular sclerosing Hodgkin's lymphoma and is treated with concurrent clozapine and systemic chemotherapy. The aim of this case report is to act as guidance for clinicians and to outline the difficulties of treating individuals with psychiatric illness under the Mental Capacity Act 2005 when the proposed treatment could lead to high levels of morbidity and mortality.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Chemotherapy for Hodgkin's lymphoma in a patient receiving clozapine for treatment-resistant schizophrenia: use of the Mental Capacity Act 2005
      Available formats
      ×
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Chemotherapy for Hodgkin's lymphoma in a patient receiving clozapine for treatment-resistant schizophrenia: use of the Mental Capacity Act 2005
      Available formats
      ×
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Chemotherapy for Hodgkin's lymphoma in a patient receiving clozapine for treatment-resistant schizophrenia: use of the Mental Capacity Act 2005
      Available formats
      ×
Copyright
This is an open-access article published by the Royal College of Psychiatrists and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Corresponding author
Correspondence to Florence Elizabeth Chamberlain (florencechamberlain@doctors.org.uk)
Footnotes
Hide All

Declaration of interest

None.

Footnotes
References
Hide All
1 Miranda, RN, Khoury, JD, Medeiros, LJ. Atlas of Lymph Node Pathology. Springer, 2013.
2 Longmore, M, Wilkinson, I, Baldwin, A, Wallin, E. Oxford Handbook of Clinical Medicine, 9th edn. Oxford University Press, 2014.
3 Office for National Statistics. Cancer Registration Statistics, England, 2011 (ONS report number 42). ONS, 2013 (http://www.ons.gov.uk/ons/dcp171778_315795.pdf).
4 Shenoy, P, Maggioncalda, A, Malik, N, Flowers, CR. Incidence patterns and outcomes for Hodgkin lymphoma patients in the United States. Adv Hematol 2011; 2011: article ID 725219.
5 Kuderer, NM, Dale, DC, Crawford, J, Cosler, LE, Lyman, GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 2006; 106: 2258–6.
6 Meltzer, HY. Treatment-resistant schizophrenia – the role of clozapine. Curr Med Res Opin 1997; 14: 120.
7 National Institute for Health and Clinical Excellence. Psychosis and Schizophrenia in Adults: Treatment and Management (Clinical Guideline 178). NICE, 2014.
8 Taylor, D, Paton, C, Kapur, S. The Maudsley Prescribing Guidelines in Psychiatry, 11th edn. John Wiley & Sons, 2012.
9 Farooq, S, Taylor, M. Clozapine: dangerous orphan or neglected friend? Br J Psychiatry 2011; 198: 247–9.
10 Joint Formulary Committee. British National Formulary, 66th edn (September 2013–March 2014). British Medical Association and Royal Pharmaceutical Society of Great Britain, 2013.
11 Munro, J, O'Sullivan, D, Andrews, C, Arana, A, Mortimer, A, Kerwin, R. Active monitoring of 12760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry 1999; 175: 576–80.
12 Huguet, G, Lillo-Le Louet, A, Darnige, L, Loo, H, Krebs, MO. Clozapine rechallenge in resistant schizophrenia disorder affecting ‘super sensitive’ patients, after neutropenia under clozapine: a case report [French]. Encephale 2013; 39: 42–8.
13 Taylor, DM, Young, C, Paton, C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J Clin Psychiatry 2003; 64: 30–4.
14 Mendelowitz, AJ, Gerson, SL, Alvir, JMJ, Lieberman, JA. Clozapine-induced agranulocytosis: risk factors, monitoring and management. CNS Drugs 1995; 4: 412–21.
15 McKenna, RC, Bailey, L, Haake, J, Desai, PN, Prasad, BR. Clozapine and chemotherapy. Hosp Comm Psychiatry 1994; 45: 831.
16 Sasieni, PD, Shelton, J, Ormiston-Smith, N, Thomson, CS, Silcocks, PB. What is the lifetime risk of developing cancer? The effect of adjusting for multiple primaries. Br J Cancer 2011; 105: 460–5.
17 Van Os, J, Kapur, S. Schizophrenia. Lancet 2009; 374: 635–45.
18 Rosenstock, J. Clozapine therapy during cancer treatment. Am J Psychiatry 2004; 161: 175.
19 Hundertmark, J, Campbell, P. Reintroduction of clozapine after diagnosis of lymphoma [letter]. Br J Psychiatry 2001; 178: 576.
20 Rosenberg, I, Mekinulov, B, Cohen, LJ, Galynker, I. Restarting clozapine treatment during ablation chemotherapy and stem cell transplant for Hodgkin's lymphoma. Am J Psychiatry 2007; 164: 1438–9.
21 Munshi, T, Mazhar, M, Hassan, T. Clozapine reinitiation following a ‘red result’ secondary to chemotherapy. Neuropsychiatr Dis Treat 2013; 9: 1267–71.
22 Alhmoud, N, Awwad, M, Jumaian, A, Shunaigat, W. Hodgkin's lymphoma in a patient with resistant schizophrenia on clozapine therapy. JRMS 2007; 14: 61–3.
23 Patel, NC, Dorson, PG, Bettinger, TL. Sudden late onset of clozapine-induced agranulocytosis. Ann Pharmacother 2002; 36: 1012–15.
24 Cohen, D, Monden, M. White blood cell monitoring during long-term clozapine treatment. Am J Psychiatry 2013; 170: 366–9.
25 Kutscher, EC, Robbins, GP, Kennedy, WK, Zebb, K, Stanley, M, Carnahan, RM. Clozapine-induced leukopenia successfully treated with lithium. Am J Health Syst Pharm 2007; 64: 2027–31.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

BJPsych Bulletin
  • ISSN: 2056-4694
  • EISSN: 2056-4708
  • URL: /core/journals/bjpsych-bulletin
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 1
Total number of PDF views: 17 *
Loading metrics...

Abstract views

Total abstract views: 26 *
Loading metrics...

* Views captured on Cambridge Core between 2nd January 2018 - 27th May 2018. This data will be updated every 24 hours.

Chemotherapy for Hodgkin's lymphoma in a patient receiving clozapine for treatment-resistant schizophrenia: use of the Mental Capacity Act 2005

  • Florence Elizabeth Chamberlain (a1), Nicholas Walsh (a2) and Jan Falkowski (a3)
Submit a response

eLetters

No eLetters have been published for this article.

×

Reply to: Submit a response


Your details


Conflicting interests

Do you have any conflicting interests? *